Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02126943 · ClinicalTrials.gov registry record
OPsumit USers Registry
A clinical trial, sponsored by Actelion.
- Completed
- Registry status
- 2,686
- Enrollment target
NCT02126943: Completed study, sponsored by Actelion.
NCT02126943 is a clinical trial that has completed, run by Actelion. The registered enrollment target is 2,686 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02126943 has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- 2,686 participants
- Enrollment target
Study Summary
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
Primary Outcome
Liver test abnormalities/ Occurrence of Hepatic Adverse Events (HAEs)/ Occurrence of any other AEs/ Discontinuation of Opsumit and reason for stopping therapy/ Hospitalization and death.
Interventions
- DRUG Opsumit (macitentan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,686 participants |
| Start Date | 2014-04-30 |
| Est. Completion | 2020-04-24 |
What the finished NCT02126943 record still lists
NCT02126943 is an observational study that tracks outcomes without assigning an intervention. Its 2,686 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Opsumit (macitentan) is the first listed.
NCT02126943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02126943 about?
NCT02126943 is a clinical study titled "OPsumit USers Registry". Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
What is the current status of trial NCT02126943?
This trial is currently completed. The enrollment target is 2,686 participants. The study started on 2014-04-30. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT02126943?
The interventions under investigation include: Opsumit (macitentan) (DRUG).
Who is sponsoring clinical trial NCT02126943?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
- NCT05471908 · 2,674 participants · NA
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI